Bruno Maria Teresa, Panella Marco Marzio, Valenti Gaetano, Ruggeri Zaira, Sgalambro Francesco, Reina Salvatore, Mereu Liliana
Gynecology and Obstetrics Unit, Department of General Surgery and Medical-Surgical Specialty, Rodolico University Hospital, University of Catania, 95124 Catania, Italy.
Multidisciplinary Research Center in Papillomavirus Pathology, Chirmed, University of Catania, 95123 Catania, Italy.
Cancers (Basel). 2024 May 28;16(11):2043. doi: 10.3390/cancers16112043.
The objective of the present study is to investigate the age-specific distribution of HPV genotypes in CIN3 lesions in screened unvaccinated women. These data are essential to optimize current and future screening programs.
A multicenter retrospective study was conducted. A total of 408 unvaccinated women with positive histology and a high-risk HPV genotype were enrolled. Each woman at baseline had HPV DNA testing and HPV genotyping, and all women underwent targeted biopsy and/or treatment with a loop electrosurgical excision procedure (LEEP) before entering the study. We divided the genotypes into HPV16/18 and HPV non-16/18 (HPV31/33/45/35/39/51/52/58/59/66/68). Women were divided into increasing age categories: <30, 30-44, and ≥45.
The percentage of CIN3 associated with HPV16/18 is maximum in women under 30 years of age (85.1%), drops to 75.6% in women aged between 30 and 44 years, and up to 47.2% in women over 45 years. CIN3 in women younger than 30 years was significantly associated with HPV16/18 genotypes ( = 0).
The data from the present study suggest that the risk of CIN3 is related to the woman's age and hr HPV genotype. The data highlight two different types of CIN3: a more frequent type, related to HPV16/18, which develops rapidly and in young women, and another, relating to non-16/18 HPV, which develops later at an advanced age and slowly, through low-grade lesions.
本研究的目的是调查未接种疫苗的筛查女性中CIN3病变的HPV基因型的年龄特异性分布。这些数据对于优化当前和未来的筛查计划至关重要。
进行了一项多中心回顾性研究。共纳入408名组织学阳性且高危HPV基因型的未接种疫苗女性。每位女性在基线时进行了HPV DNA检测和HPV基因分型，所有女性在进入研究前均接受了靶向活检和/或环形电切术（LEEP）治疗。我们将基因型分为HPV16/18和HPV非16/18（HPV31/33/45/35/39/51/52/58/59/66/68）。女性被分为年龄递增类别：<30岁、30-44岁和≥45岁。
与HPV16/18相关的CIN3百分比在30岁以下女性中最高（85.1%），在30至44岁女性中降至75.6%，在45岁以上女性中高达47.2%。30岁以下女性的CIN3与HPV16/18基因型显著相关（=0）。
本研究的数据表明，CIN3的风险与女性年龄和高危型HPV基因型有关。数据突出了两种不同类型的CIN3：一种更常见的类型，与HPV16/18相关，在年轻女性中迅速发展；另一种与非16/18型HPV相关，在老年时通过低度病变缓慢发展。
